14.01.2013 Views

Profilaksa DVT kod velikih ortopedskih operacija - Depol ...

Profilaksa DVT kod velikih ortopedskih operacija - Depol ...

Profilaksa DVT kod velikih ortopedskih operacija - Depol ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

20 - 22 September 2012, Opatija, Croatia<br />

OSTEOGENIC POTENTIAL AND STEMNESS OF MESENCHYMAL<br />

STEM CELLS AFTER DEXAMETHASONE TREATMENT<br />

Andreja Vukasovic, Department of Histology and Embryology, School of Medicine, University of Zagreb,<br />

Zagreb, Croatia<br />

Davor Jezek, Department of Histology and Embryology, School of Medicine, University of Zagreb, Zagreb,<br />

Croatia<br />

Petar Kostesic, Clinic for Surgery, Orthopedics and Ophthalmology, Faculty of Veterinary Medicine,<br />

University of Zagreb, Zagreb, Croatia<br />

Damir Hudetz, Department of Orthopedics, University Hospital Sveti Duh, Zagreb, Croatia<br />

Ivan Cerovecki, School of Medicine, University of Zagreb, Zagreb, Croatia<br />

Marin Kosovic, Department of Physics and Biophysics, School of Medicine, University of Zagreb, Zagreb,<br />

Croatia<br />

Tadija Petrovic, Clinic for Traumatology, Clinical Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia<br />

Drazen Maticic, Clinic for Surgery, Orthopedics and Ophthalmology, Faculty of Veterinary Medicine,<br />

University of Zagreb, Zagreb, Croatia<br />

Alan Ivkovic, Department of Orthopedics, University Hospital Sveti Duh, Zagreb, Croatia<br />

Marko Pecina, School of Medicine, University of Zagreb, Zagreb, Croatia<br />

The purpose of the research was to improve osteogenic differentiation of human bone marrow derived-mesenchymal<br />

stem cells (hMSCs) and to evaluate the level of remaining undifferentiated stem cells in culture. Standard<br />

cell culture protocol includes continuous exposure to the dexamethasone which is not easy to reproduce in human<br />

body. Therefore, our experiment was designed to investigate the possibility of using short-term dexamethasone<br />

exposure in order to induce osteogenic differentiation.<br />

Human bone marrow-derived MSCs were expanded with FGF-2 supplemented media. Afterwards cells were cultured<br />

in osteogenic media (DMEM low glucose, 10% FBS, 10mM β-glycerophosphate, 5µg/ml ascorbic acid, 1mM<br />

piruvat) and treated with different concentrations of dexamethasone, both short-term and continuous. The differentiation<br />

status of the cells was estimated using several osteogenic markers - alkaline phosphatase (AP) activity,<br />

the bone sialoprotein (BSP) and dentin matrix protein 1 (DMP-1) mRNAs. The stemness of the cells was estimated<br />

by the presence of pluripotency markers - SRY (sex determining region Y)-box 2 (SOX2) and octamer-binding transcription<br />

factor 4 (OCT4). The measurements were conducted on the days 7 and 14 after osteogenic conditions<br />

had been introduced.<br />

Our results show that continuous treatment induces the highest level of osteogenesis, but 2 hour exposure also induced<br />

differentiation in comparison with control. Overall, 10-5 M concentration of dexamethasone was the most<br />

powerful in the short-term induction of osteogenesis. SOX2 has not been detected in hMSCs. OCT4 was expressed<br />

in undifferentiated pluripotent hMSCs and its expression subsequently went down, indicating that the differentiation<br />

process is proceeding.<br />

Poster<br />

91

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!